Clinical trial
A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT04435366 is registered in ClinicalTrials.gov with IVERIC bio, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Multicenter, Randomized, Double Masked, Sham- Controlled Clinical Trial to Assess the Safety and Efficacy of Intravitreal Administration of Zimura (Complement C5 Inhibitor) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
- Lead sponsor
- IVERIC bio, Inc.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- June 22, 2020
- Completion date
- August 22, 2023
- Enrollment
- 448 (actual)
- Sites
- 205
Conditions
As the registry lists them; a condition with its own page is linked.